InvestorsHub Logo
Followers 272
Posts 53131
Boards Moderated 3
Alias Born 08/16/2008

Re: None

Thursday, 05/18/2023 9:45:59 AM

Thursday, May 18, 2023 9:45:59 AM

Post# of 1032
ALIM I got in for a play

https://stockcharts.com/h-sc/ui?s=ALIM

BRIEF-Alimera Acquires U.S. Commercial Rights To Yutiq®
REUTERS
7:05 AM ET May-18-2023
May 18 (Reuters) - Alimera Sciences Inc (ALIM.NaE):

* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ®

* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ® Source text for Eikon: Further company coverage:


Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALIM News